ethyl 2,3-dihydro-3-oxo-6-(4-pyridinyl)-4-pyridazinecarboxylate | 80843-54-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: ethyl 2,3-dihydro-3-oxo-6-(4-pyridinyl)-4-pyridazinecarboxylate
• 英文别名: 3-oxo-6-pyridin-4-yl-2,3-dihydro-pyridazine-4-carboxylic acid ethyl ester；Ethyl 3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazine-4-carboxylate；ethyl 6-oxo-3-pyridin-4-yl-1H-pyridazine-5-carboxylate
• CAS: 80843-54-5
• 化学式: C₁₂H₁₁N₃O₃
• 分子量: 245.238
• InChiKey: JFGAMCHVJAGCJO-UHFFFAOYSA-N

物化性质

• 熔点：
  196-197 °C
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 2,3-dihydro-3-oxo-6-(4-pyridinyl)-4-pyridazinecarboxylate 在 sodium hydroxide 、 溶剂黄146 作用下， 以 P2 O5 为溶剂， 生成 2,3-dihydro-3-oxo-6-(4-pyridinyl)-4-pyridazinecarboxylic acid
  参考文献：
  名称：

  4-Amino-6-(pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics

  摘要：

  4-氨基-2-R-6-PY-3(2H)-吡啶并嗪酮(I)或其盐，可用作心力衰竭药物，其中R为氢、低烷基或低羟基烷基，PY为4-或3-吡啶基或带有一个或两个低烷基取代基的4-或3-吡啶基，通过以下方法制备：(a) 2-R-6-PY-3(2H)-吡啶并嗪酮(II)与肼的反应；(b) 从2,3-二氢-2-R-3-氧代-6-PY-4-吡啶并嗪甲酰胺(III)转化而来；或(c) 从2,3-二氢-2-R-3-氧代-6-PY-4-吡啶并嗪羧酸肼酰肼(IV)转化而来。还显示了：将I或其盐用作心力衰竭药物；以及中间体的制备。

  公开号：

  US04305943A1
• 作为产物：
  描述：

  diethyl hydroxy<2-oxo-2-(4-pyridinyl)ethyl>propanedioate 在 盐酸肼 作用下， 以 乙醇 为溶剂， 反应 18.0h， 以71%的产率得到ethyl 2,3-dihydro-3-oxo-6-(4-pyridinyl)-4-pyridazinecarboxylate
  参考文献：
  名称：

  Synthesis of Aza Analogs of Amrinone

  摘要：

  The aldol condensation product (4) of 4-acetylpyridine (2) and diethyl mesoxalate (3) was converted to pyridazinecarboxylic acid hydrazide (6). Curtius reaction of 6 gave aminopyridazinone (7). The condensation of (4-pyridinyl)glyoxal (17) with aminomalonamide (9) yielded pyrazinecarboxamide (18) which was transformed to aminopyrazinone (19) by the Hofmann reaction. Curtius reaction of 1,2,4-triazinone-5-carboxylic acid (21b) gave aminotriazinone (22). Demethylation of methoxypyrimidine (29) prepared from methyl 2-methoxyformylacetate (25) and isonicotinamidine (26) gave pyrimidinol (30).

  DOI：

  10.3987/com-90-5562

文献信息

• Novel pyridazinone derivatives as inhibitors of CDK2
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1598348A1

  公开（公告）日：2005-11-23

  The present invention relates to compounds according to the general formula (I), with the definitions of the substituents X, R1 and R2 given below in the text, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2)

  本发明涉及符合通式（I）的化合物，其中下文给出了取代基X、R1和R2的定义，以及它们的生理上可接受的盐，以及制备这些化合物的方法以及它们作为药物的用途。 这些化合物是激酶抑制剂，特别是激酶CDK2（细胞周期依赖性激酶2）的抑制剂。
• [EN] PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS<br/>[FR] DERIVES DE PYRIDAZINONE, PROCEDES DE PRODUCTION DE CES DERIVES ET LEUR UTILISATION COMME PHARMACEUTIQUES
  申请人：AVENTIS PHARMA GMBH

  公开号：WO2005111018A1

  公开（公告）日：2005-11-24

  The present invention relates to compounds according to the general formula (I), with the definitions of the substituents X, R1 and R2 given below in the text, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. Formula (I) These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK­15 30 (glycogen synthase kinase-3ß).

  本发明涉及通式（I）所示的化合物，其中下文给出了取代基X、R1和R2的定义，以及它们的生理上可接受的盐，生产这些化合物的方法以及它们作为药物的用途。通式（I）这些化合物是激酶抑制剂，特别是激酶GSK-15 30（糖原合成酶激酶-3ß）的抑制剂。
• 4-Amino-6-(pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics
  申请人：Sterling Drug Inc.

  公开号：US04305943A1

  公开（公告）日：1981-12-15

  4-Amino-2-R-6-PY-3(2H)-pyridazinones (I) or salts thereof, which are useful as cardiotonics, where R is hydrogen, lower-alkyl or lower-hydroxyalkyl, and PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents are prepared by: (a) reaction of 2-R-6-PY-3(2H)-pyridazinone (II) with hydrazine; (b) conversion from 2,3-dihydro-2-R-3-oxo-6-PY-4-pyridazinecarboxamide (III); or, (c) conversion form 2,3-dihydro-2-R-3-oxo-6-PY-4-pyridazinecarboxylic acid hydrazide (IV). Also shown are: the use of I or salts as cardiotonic agents; and, the preparation of intermediates.

  4-氨基-2-R-6-PY-3(2H)-吡啶并嗪酮(I)或其盐，可用作心力衰竭药物，其中R为氢、低烷基或低羟基烷基，PY为4-或3-吡啶基或带有一个或两个低烷基取代基的4-或3-吡啶基，通过以下方法制备：(a) 2-R-6-PY-3(2H)-吡啶并嗪酮(II)与肼的反应；(b) 从2,3-二氢-2-R-3-氧代-6-PY-4-吡啶并嗪甲酰胺(III)转化而来；或(c) 从2,3-二氢-2-R-3-氧代-6-PY-4-吡啶并嗪羧酸肼酰肼(IV)转化而来。还显示了：将I或其盐用作心力衰竭药物；以及中间体的制备。
• Pyridazines as interleukin-1beta converting enzyme inhibitors
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20040110725A1

  公开（公告）日：2004-06-10

  Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: 1 wherein R 1 is a halogen, or an oxygen linked leaving group including an aromatic ether, an alkyl sulfonate, an aryl sulfonate, an alkyl phosphonate, an aryl phosphonate, an alkyl phosphate or aryl phosphate; R 2 is COOR 5 , C(═O)NH(CHR 5 ) m —COOR 5 , NH(CHR 5 ) m CON(R 5 )R 6 , C(═O)N(R 5 )R 6 or NH(CHR 5 ) m OH; R 3 is H or alkyl; R 4 is H, sybstituted or unsubstituted aryl, heteroaryl or alkyl; R 5 and R 6 are independently H, lower alkyl, aryl, hydroxy alkyl, amino alkyl, heteroaryl, lower alkylene-aryl, lower alkylene-heteroaryl or lower cycloalkyl; and m=0-6; pharmaceutical compositions containing the compounds; and a method for inhibiting interleukin-1&bgr; protease activity in a mammal utilizing the compounds and compositions.

  本发明涉及式(I)的化合物及其药学上可接受的盐：1其中R1是卤素或含芳香醚、烷基磺酸酯、芳基磺酸酯、烷基膦酸酯、芳基膦酸酯、烷基磷酸酯或芳基磷酸酯的氧链离去基；R2是COOR5、C(═O)NH(CHR5)m—COOR5、NH(CHR5)mCON(R5)R6、C(═O)N(R5)R6或NH(CHR5)mOH；R3是氢或烷基；R4是氢、取代或未取代的芳基、杂芳基或烷基；R5和R6独立地是氢、低烷基、芳基、羟基烷基、氨基烷基、杂芳基、低烷基-芳基、低烷基-杂芳基或低环烷基；m=0-6；含有这些化合物的药物组合物；以及利用这些化合物和组合物抑制哺乳动物中白细胞介素-1β蛋白酶活性的方法。
• PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS
  申请人：Hoelder Swen

  公开号：US20070088041A1

  公开（公告）日：2007-04-19

  The present invention relates to compounds according to the general formula (I), with the definitions of the substituents X, R 1 and R 2 given below in the text, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK-3β(glycogen synthase kinase-3β).

  本发明涉及符合通式（I）的化合物，其中X，R1和R2的定义如下文所述，以及它们的生理学上可接受的盐，制备这些化合物的方法以及它们作为药物的用途。这些化合物是激酶抑制剂，特别是激酶GSK-3β（糖原合成酶激酶-3β）的抑制剂。